Question 1

What is combined oxidative phosphorylation deficiency 38?

Accepted Answer

Combined oxidative phosphorylation deficiency 38 is a multisystem condition that affects energy production in the body, with a significant impact on the nervous system, heart, respiratory function, and metabolic processes. This condition is linked to pathogenic variants in the MRPS14 gene, which plays a critical role in mitochondrial protein synthesis and energy generation. Affected individuals typically present in infancy with developmental delays and other systemic findings, although precise prevalence estimates are not well established. Overall, the condition reflects a complex disruption of mitochondrial function that manifests early in life.

Question 2

What are the symptoms of combined oxidative phosphorylation deficiency 38?

Accepted Answer

The clinical presentation is characterized by consistent and multisystem features. Neurologically, affected individuals exhibit delayed speech and language development, global developmental delay, and generalized hypotonia. Additionally, there are clear cardiac manifestations including hypertrophic cardiomyopathy and Wolff-Parkinson-White syndrome. Metabolic abnormalities such as increased circulating lactate concentration, lactic acidosis, and hyperalaninemia are evident, along with distinct facial and skeletal features like midface retrusion, a depressed nasal bridge, low-set and posteriorly rotated ears, and failure to thrive. Abnormal mitochondrial morphology further underscores the mitochondrial dysfunction. Not all individuals experience all features, and severity varies considerably.

Question 3

What causes combined oxidative phosphorylation deficiency 38?

Accepted Answer

Combined oxidative phosphorylation deficiency 38 results from pathogenic variants in the MRPS14 gene. MRPS14 encodes a protein that is a key component of the mitochondrial ribosome, which is essential for synthesizing proteins required for oxidative phosphorylation. The disruption in mitochondrial protein synthesis leads to decreased activity of several mitochondrial complexes, contributing to the metabolic, neurological, and cardiac abnormalities seen in this condition. This disorder is inherited in an autosomal recessive pattern, meaning that an affected individual has inherited a defective copy of the gene from each parent. Genetic counseling is recommended for families to understand the implications and recurrence risks associated with this inheritance pattern. Associated genes include MRPS14.

Question 4

How is combined oxidative phosphorylation deficiency 38 inherited?

Accepted Answer

combined oxidative phosphorylation deficiency 38 follows an autosomal recessive inheritance pattern. This means a child must inherit a copy of the altered gene from both parents to develop the condition. Parents who each carry one copy typically do not show symptoms.

Question 5

How is combined oxidative phosphorylation deficiency 38 diagnosed?

Accepted Answer

Diagnosis is confirmed through molecular genetic testing identifying pathogenic variants in MRPS14. In addition, a comprehensive clinical evaluation is performed to assess the characteristic features such as developmental delays, metabolic abnormalities, cardiac issues, and distinct facial features. Laboratory findings, including evidence of lactic acidosis and abnormal mitochondrial enzyme activities, support the clinical suspicion. Because many of these features can overlap with other conditions, definitive diagnosis relies on genetic testing in conjunction with the clinical and biochemical evaluation.

Question 6

Are there treatments for combined oxidative phosphorylation deficiency 38?

Accepted Answer

Currently, management focuses on supportive care and symptom management as there are no treatments specifically approved for combined oxidative phosphorylation deficiency 38. Treatment is tailored to the individual and typically involves a multidisciplinary team that may include cardiologists, neurologists, and metabolic specialists. Regular surveillance is an essential part of long-term care, helping to identify potential complications before they become serious. Genetic counseling is recommended to help families understand treatment options and the implications of the autosomal recessive inheritance pattern.

Question 7

What are the potential complications of combined oxidative phosphorylation deficiency 38?

Accepted Answer

Combined oxidative phosphorylation deficiency 38 can lead to several complications due to its multisystem effects. Individuals may experience significant cardiac issues, such as hypertrophic cardiomyopathy, which can affect heart function. Additionally, neurological challenges like developmental delays and hypotonia can impact daily activities and overall quality of life.

Question 8

How does combined oxidative phosphorylation deficiency 38 affect daily life for patients and families?

Accepted Answer

Living with combined oxidative phosphorylation deficiency 38 can be challenging for both patients and families. Daily life may involve managing developmental delays and coordinating care with various specialists, such as cardiologists and neurologists. Supportive care and regular monitoring are essential to address the condition's symptoms and improve the quality of life.

Question 9

What is the prognosis for individuals with combined oxidative phosphorylation deficiency 38?

Accepted Answer

The prognosis for individuals with combined oxidative phosphorylation deficiency 38 varies widely based on the severity of the condition. While many face significant challenges, advancements in supportive care have improved quality of life over time. Some individuals may experience periods of stability, but ongoing monitoring and management are crucial for addressing potential complications.

Question 10

What specific symptoms should families watch for in combined oxidative phosphorylation deficiency 38?

Accepted Answer

Families should be aware of several specific symptoms associated with combined oxidative phosphorylation deficiency 38. These include developmental delays, hypotonia, and distinct facial features like midface retrusion and low-set ears. Cardiac symptoms, such as hypertrophic cardiomyopathy, and metabolic issues like lactic acidosis are also important to monitor.

Research Type	Count	% of Total
Laboratory research	21	60%

Kisho

combined oxidative phosphorylation deficiency 38

Overview

Clinical Presentation

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Medical References

External Resources

OMIM

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

Explore clinical features

Recent Publications

combined oxidative phosphorylation deficiency 38

Overview

Clinical Presentation

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Medical References

External Resources

OMIM

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

What is combined oxidative phosphorylation deficiency 38?

What are the symptoms of combined oxidative phosphorylation deficiency 38?

What causes combined oxidative phosphorylation deficiency 38?

How is combined oxidative phosphorylation deficiency 38 inherited?

How is combined oxidative phosphorylation deficiency 38 diagnosed?

Are there treatments for combined oxidative phosphorylation deficiency 38?

What are the potential complications of combined oxidative phosphorylation deficiency 38?

How does combined oxidative phosphorylation deficiency 38 affect daily life for patients and families?

What is the prognosis for individuals with combined oxidative phosphorylation deficiency 38?

What specific symptoms should families watch for in combined oxidative phosphorylation deficiency 38?

Explore clinical features

Recent Publications